当前位置:首页>产品中心>单抗/多抗>Anti-CHIKV Spike glycoprotein E1 Polyclonal Antibody|抗CHIKV刺突糖蛋白E1多克隆抗体(靶标:基孔肯雅病毒刺突糖蛋白E1)

Anti-CHIKV Spike glycoprotein E1 Polyclonal Antibody|抗CHIKV刺突糖蛋白E1多克隆抗体(靶标:基孔肯雅病毒刺突糖蛋白E1)

  • 货号:RB9TVK425014
  • 价格:面议
  • 点击:431

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯度>90% as determined by SDS-PAGE.
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
已验证应用WB, ELISA
应用WB, IHC, ELISA
种属反应性Chikungunya virus, O'nyong-nyong virus
靶标CHIKV-E1
免疫原E. coli - derived recombinant CHIKV Structural polyprotein (Tyr810-Lys1221).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q8JUX5, Q5WQY5, Q5XXP3, O90371, P22056, O90369
背景信息Chikungunya virus (CHIKV) is a mosquito-borne alphavirus responsible for Chikungunya fever, a disease marked by fever, rash, and joint pain. The E1 envelope glycoprotein, a 47 kDa class II fusion protein, plays a critical role in viral entry by mediating low pH-triggered membrane fusion within host endosomes. It forms heterodimers with E2 glycoproteins, assembling into spike trimers on the viral surface that facilitate host cell attachment and infection. Due to its essential function in viral infectivity, the E1 protein is widely used in studies of viral entry, antibody development, vaccine design, and diagnostic assay optimization.
• Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8., PMID:37804831
• Changes in the chikungunya virus E1 glycoprotein domain II and hinge influence E2 conformation, infectivity, and virus-receptor interactions., PMID:38842335
• Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity., PMID:35416719
• The chikungunya virus E1 glycoprotein fusion loop and hinge alter glycoprotein dynamics leading to cell and host specific changes in infectivity., PMID:37961096
• Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus., PMID:36016401
• Enhanced Molecular Surveillance of Chikungunya Virus., PMID:31270168
• Cell-based analysis of Chikungunya virus E1 protein in membrane fusion., PMID:22520648
• Promising application of monoclonal antibody against chikungunya virus E1-antigen across genotypes in immunochromatographic rapid diagnostic tests., PMID:32615978
• Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication., PMID:23056297
• A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice., PMID:39440961
别名Structural polyprotein, p130, Capsid protein, 3.4.21.90, Coat protein, C, Precursor of protein E3/E2, p62, pE2, Assembly protein E3, Spike glycoprotein E2, E2 envelope glycoprotein, 6K protein, Spike glycoprotein E1, E1 envelope glycoprotein
种属Chikungunya virus (strain S27-African prototype) (CHIKV)
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 585
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 394
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 613
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 343
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 492
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 634
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 588
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 682
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 520
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 341
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 476
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 384
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 603
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 560
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 529
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 654
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 350
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 389
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 363
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 388
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00